Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Onyalai.

P B Hesseling

    Bailliere'S Clinical Haematology
    |April 1, 1992
    PubMed
    Summary
    This summary is machine-generated.

    Onyalai is a severe immune thrombocytopenia affecting Black populations in Southern Africa, characterized by hemorrhagic bullae. Early treatment significantly reduced mortality, though its cause remains unknown.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Burkitt's lymphoma: The prevalence of HIV/AIDS and the outcome of treatment.

    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2018
    Same author

    Kaposi's sarcoma: Good outcome with doxorubicin, bleomycin and vincristine sulphate (ABV) chemotherapy and highly active antiretroviral therapy.

    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2017
    Same author

    Burkitt's lymphoma patients in Northwest Cameroon have a lower incidence of sickle cell trait (Hb AS) than healthy controls.

    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2016
    Same author

    Endemic Burkitt Lymphoma: Long-term Outcome in 87 Patients Who Presented With Paraplegia in Cameroon.

    Pediatric hematology and oncology·2015
    Same author

    Letter to the editor.

    Pediatric blood & cancer·2014
    Same author

    Epidemiology of Burkitt's lymphoma in Northwest Province, Cameroon, 2003-2010.

    Paediatrics and international child health·2012
    Same journal

    Current status of stem cell therapy and prospects for gene therapy for the disorders of globin synthesis.

    Bailliere's clinical haematology·2000
    Same journal

    Pharmacological therapy.

    Bailliere's clinical haematology·2000
    Same journal

    Prenatal diagnosis and screening of the haemoglobinopathies.

    Bailliere's clinical haematology·2000
    Same journal

    Sickle cell disease: clinical management.

    Bailliere's clinical haematology·2000
    Same journal

    Pathophysiology of sickle cell disease.

    Bailliere's clinical haematology·2000
    Same journal

    Thalassaemia: clinical management.

    Bailliere's clinical haematology·2000
    See all related articles

    Area of Science:

    • Hematology
    • Immunology
    • Epidemiology

    Background:

    • Onyalai is an acquired immune thrombocytopenia distinct from idiopathic thrombocytopenic purpura.
    • It is prevalent in specific Black populations in Southern Africa, with a notable incidence in Namibia.
    • The condition presents with severe hemorrhagic bullae in the oronasopharynx, potentially leading to shock and death.

    Purpose of the Study:

    • To differentiate Onyalai from idiopathic thrombocytopenic purpura.
    • To describe the clinical, epidemiological, and immunological characteristics of Onyalai.
    • To evaluate treatment outcomes and explore potential etiologies.

    Main Methods:

    • Clinical observation and case analysis.
    • Immunological assays for serum platelet antibodies (IgG, IgM) and autoantibodies.

    Related Experiment Videos

  • Epidemiological data collection on incidence and affected populations.
  • Review of treatment strategies and their impact on mortality and platelet counts.

    • Main Results:

    • Onyalai is characterized by hemorrhagic bullae, severe bleeding, and is endemic to specific African populations.
    • Patients often exhibit IgG, IgM, and anti-glycoprotein IIb/IIIa antibodies.
    • Mortality decreased from 9.8% to 2.8% with shock prevention; standard prednisolone was ineffective, while vincristine, splenectomy, and IVIg showed potential benefits.

    Conclusions:

    • Onyalai is a distinct immune thrombocytopenia with significant morbidity and mortality, particularly in affected African regions.
    • Effective management focuses on preventing hemorrhagic shock, with specific treatments like IVIg and splenectomy reserved for severe cases.
    • The etiology of Onyalai is unknown, with mycotoxins suggested as a potential factor requiring further research.